Cargando…

Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial

The aim of this study is to investigate the glycemic profile, oxidative stress, and antioxidant capacity in athletes after 12 weeks of ubiquinone supplementation. It was a double-blinded, randomized, parallel, placebo-controlled study. Thirty-one well-trained college athletes were randomly assigned...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Chien-Chang, Chang, Po-Sheng, Chen, Hung-Wun, Lee, Po-Fu, Chang, Yun-Chi, Tseng, Ching-Yu, Lin, Ping-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555239/
https://www.ncbi.nlm.nih.gov/pubmed/32899227
http://dx.doi.org/10.3390/antiox9090823
_version_ 1783593961408954368
author Ho, Chien-Chang
Chang, Po-Sheng
Chen, Hung-Wun
Lee, Po-Fu
Chang, Yun-Chi
Tseng, Ching-Yu
Lin, Ping-Ting
author_facet Ho, Chien-Chang
Chang, Po-Sheng
Chen, Hung-Wun
Lee, Po-Fu
Chang, Yun-Chi
Tseng, Ching-Yu
Lin, Ping-Ting
author_sort Ho, Chien-Chang
collection PubMed
description The aim of this study is to investigate the glycemic profile, oxidative stress, and antioxidant capacity in athletes after 12 weeks of ubiquinone supplementation. It was a double-blinded, randomized, parallel, placebo-controlled study. Thirty-one well-trained college athletes were randomly assigned to ubiquinone (300 mg/d, n = 17) or placebo group (n = 14). The glycemic profile [fasting glucose, glycated hemoglobin (HbA1c), homeostatic model assessment-insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI)], plasma and erythrocyte malondialdehyde (MDA), total antioxidant capacity (TAC), and ubiquinone status were measured. After supplementation, the plasma ubiquinone concentration was significantly increased (p < 0.05) and the level of erythrocyte MDA was significantly lower in the ubiquinone group than in the placebo group (p < 0.01). There was a significant correlation between white blood cell (WBC) ubiquinone and glycemic parameters [HbA1c, r = −0.46, p < 0.05; HOMA-IR, r = −0.67, p < 0.01; QUICKI, r = 0.67, p < 0.01]. In addition, athletes with higher WBC ubiquinone level (≥0.5 nmol/g) showed higher erythrocyte TAC and QUICKI and lower HOMA-IR. In conclusion, we demonstrated that athletes may show a better antioxidant capacity with higher ubiquinone status after 12 weeks of supplementation, which may further improve glycemic control.
format Online
Article
Text
id pubmed-7555239
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75552392020-10-19 Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial Ho, Chien-Chang Chang, Po-Sheng Chen, Hung-Wun Lee, Po-Fu Chang, Yun-Chi Tseng, Ching-Yu Lin, Ping-Ting Antioxidants (Basel) Article The aim of this study is to investigate the glycemic profile, oxidative stress, and antioxidant capacity in athletes after 12 weeks of ubiquinone supplementation. It was a double-blinded, randomized, parallel, placebo-controlled study. Thirty-one well-trained college athletes were randomly assigned to ubiquinone (300 mg/d, n = 17) or placebo group (n = 14). The glycemic profile [fasting glucose, glycated hemoglobin (HbA1c), homeostatic model assessment-insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI)], plasma and erythrocyte malondialdehyde (MDA), total antioxidant capacity (TAC), and ubiquinone status were measured. After supplementation, the plasma ubiquinone concentration was significantly increased (p < 0.05) and the level of erythrocyte MDA was significantly lower in the ubiquinone group than in the placebo group (p < 0.01). There was a significant correlation between white blood cell (WBC) ubiquinone and glycemic parameters [HbA1c, r = −0.46, p < 0.05; HOMA-IR, r = −0.67, p < 0.01; QUICKI, r = 0.67, p < 0.01]. In addition, athletes with higher WBC ubiquinone level (≥0.5 nmol/g) showed higher erythrocyte TAC and QUICKI and lower HOMA-IR. In conclusion, we demonstrated that athletes may show a better antioxidant capacity with higher ubiquinone status after 12 weeks of supplementation, which may further improve glycemic control. MDPI 2020-09-03 /pmc/articles/PMC7555239/ /pubmed/32899227 http://dx.doi.org/10.3390/antiox9090823 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ho, Chien-Chang
Chang, Po-Sheng
Chen, Hung-Wun
Lee, Po-Fu
Chang, Yun-Chi
Tseng, Ching-Yu
Lin, Ping-Ting
Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial
title Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_full Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_fullStr Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_full_unstemmed Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_short Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_sort ubiquinone supplementation with 300 mg on glycemic control and antioxidant status in athletes: a randomized, double-blinded, placebo-controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555239/
https://www.ncbi.nlm.nih.gov/pubmed/32899227
http://dx.doi.org/10.3390/antiox9090823
work_keys_str_mv AT hochienchang ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial
AT changposheng ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial
AT chenhungwun ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial
AT leepofu ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial
AT changyunchi ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial
AT tsengchingyu ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial
AT linpingting ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial